Literature DB >> 19560922

Bis-anthracenyl isoxazolyl amides have enhanced anticancer activity.

Mariusz P Gajewski1, Howard Beall, Mark Schnieder, Sarah M Stranahan, Michael D Mosher, Kevin C Rider, Nicholas R Natale.   

Abstract

Dimeric analogs of Anthracenyl Isoxazole Amides (AIMs) (the designation AIM is in honor of the memory of Professor Albert I. Meyers) were prepared and dimer 6 exhibited the highest efficacy to date for this class of anti-tumor compounds against the human glioma Central Nervous System cell line SNB-19.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19560922      PMCID： PMC2731571          DOI： 10.1016/j.bmcl.2009.06.019

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN： 0960-894X            Impact factor:   2.823


  7 in total

1.  Direct evidence for a G-quadruplex in a promoter region and its targeting with a small molecule to repress c-MYC transcription.

Authors:  Adam Siddiqui-Jain; Cory L Grand; David J Bearss; Laurence H Hurley
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-23       Impact factor: 11.205

2.  (3 + 1) Assembly of three human telomeric repeats into an asymmetric dimeric G-quadruplex.

Authors:  Na Zhang; Anh Tuân Phan; Dinshaw J Patel
Journal:  J Am Chem Soc       Date:  2005-12-14       Impact factor: 15.419

3.  The new models of the human telomere d[AGGG(TTAGGG)3] in K+ solution.

Authors:  Yan Xu; Yuki Noguchi; Hiroshi Sugiyama
Journal:  Bioorg Med Chem       Date:  2006-05-08       Impact factor: 3.641

Review 4.  Targeting telomeres and telomerase.

Authors:  Anne De Cian; Laurent Lacroix; Céline Douarre; Nassima Temime-Smaali; Chantal Trentesaux; Jean-François Riou; Jean-Louis Mergny
Journal:  Biochimie       Date:  2007-07-24       Impact factor: 4.079

Review 5.  A hitchhiker's guide to G-quadruplex ligands.

Authors:  David Monchaud; Marie-Paule Teulade-Fichou
Journal:  Org Biomol Chem       Date:  2007-11-14       Impact factor: 3.876

6.  Design, synthesis, and antitumor activity of new bis-aminomethylnaphthalenes.

Authors:  Mariela Bollini; Juan José Casal; Ana María Bruno
Journal:  Bioorg Med Chem       Date:  2008-07-29       Impact factor: 3.641

7.  Design, synthesis and biological evaluation of a novel class of anticancer agents: anthracenylisoxazole lexitropsin conjugates.

Authors:  Xiaochun Han; Chun Li; Michael D Mosher; Kevin C Rider; Peiwen Zhou; Ronald L Crawford; William Fusco; Andrzej Paszczynski; Nicholas R Natale
Journal:  Bioorg Med Chem       Date:  2008-12-31       Impact factor: 3.641
  7 in total
  5 in total

1.  AIMing towards improved antitumor efficacy.

Authors:  Matthew J Weaver; Alison K Kearns; Sascha Stump; Chun Li; Mariusz P Gajewski; Kevin C Rider; Donald S Backos; Philip R Reigan; Howard D Beall; Nicholas R Natale
Journal:  Bioorg Med Chem Lett       Date:  2015-03-03       Impact factor: 2.823

2.  Improved synthesis of 3-aryl isoxazoles containing fused aromatic rings.

Authors:  Yousef R Mirzaei; Matthew J Weaver; Scott A Steiger; Alison K Kearns; Mariusz P Gajewski; Kevin C Rider; Howard D Beall; N R Natale
Journal:  Tetrahedron       Date:  2012-09-25       Impact factor: 2.457

3.  Ethyl 3-(9-chloro-10-oxo-9,10-di-hydro-anthracen-9-yl)-5-methyl-isoxazole-4-carboxyl-ate.

Authors:  Nathan S Duncan; Howard D Beall; Alison K Kearns; Chun Li; Nicholas R Natale
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2014-02-19

4.  Ethyl 3-(10-bromo-anthracen-9-yl)-5-methyl-1,2-oxazole-4-carboxyl-ate.

Authors:  Chun Li; Michael J Campbell; Matthew J Weaver; Nathan S Duncan; Janet L Hunting; Nicholas R Natale
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2013-11-23

5.  Design and synthesis of new bis(1,2,4-triazolo[3,4-b][1,3,4]thiadiazines) and bis((quinoxalin-2-yl)phenoxy)alkanes as anti-breast cancer agents through dual PARP-1 and EGFR targets inhibition.

Authors:  Fatma M Thabet; Kamal M Dawood; Eman A Ragab; Mohamed S Nafie; Ashraf A Abbas
Journal:  RSC Adv       Date:  2022-08-19       Impact factor: 4.036
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.